Amicus Therapeutics, Inc. Aktie News

Amicus Therapeutics (FOLD) is progressing toward profitability, driven by strong Q3 results and expanding global approvals for its rare disease therapies. FOLD's revenue grew 19.5% year-over-year, with Galafold and Pombiliti + Opfolda showing robust sales growth and management reaffirming FY2025 guidance. Amicus recently added DMX-200 to pipeline, licensing it from Dimerix, and targets FSGS, a ...

Amicus Therapeutics, Inc. ( FOLD ) UBS Global Healthcare Conference 2025 November 10, 2025 2:45 PM EST Company Participants Jeffrey Castelli - Chief Development Officer Presentation Unknown Analyst Great. Okay. Well, thanks, everyone, for joining us.

Amicus Therapeutics, Inc. ( FOLD ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley Campbell - CEO, President & Director Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Simon Nicolas Harford - Chief Financial Officer Conference Call Participants Joseph Schwartz - Leerink ...

Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J.

PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.

PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m.

Amicus Therapeutics remains a Buy, supported by strong momentum in Galafold and Pombiliti/Opfolda, both with blockbuster potential. FOLD's Galafold leads in Fabry disease as the first oral precision medicine, with global expansion and robust IP protection through 2036. Pombiliti/Opfolda addresses unmet needs in Pompe disease, showing solid uptake and payer acceptance despite premium pricing.

Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.